Research use only. Not for use in diagnostic procedures.

Fluorescent Imaging Agent

IVISense™ Transferrin Receptor 750 Fluorescent Probe

Product Number: NEV10091

DESCRIPTION

IVISense™ Transferrin Receptor 750 Fluorescent Probe is a fluorescently-labeled protein designed to bind to transferrin receptors over-expressed in cancer cell with rapid proliferation.

MATERIAL


Each vial contains 24 nmol of IVISense™ Transferrin Receptor 750 Fluorescent Probe as a dry solid. The solution of IVISense™ Transferrin Receptor 750 Fluorescent Probe has been filtered through a 0.2 µm filter prior to lyophilization. Upon reconstitution with 1.2 mL of 1 x PBS, this material provides sufficient reagent for imaging approximately 10 mice (weighing ~25 grams each) when using the recommended dose of 2 nmol/100 µL 1xPBS of IVISense™ Transferrin Receptor 750 Fluorescent Probe per mouse.

STORAGE	Ω.	$\square \land \square$	וחו	INIC

- Upon receipt, IVISense[™] Transferrin Receptor 750
 Fluorescent Probe should be IMMEDIATELY
 STORED AT -20 °C AND PROTECTED FROM LIGHT.
- When stored and handled properly, IVISense™
 Transferrin Receptor 750 Fluorescent Probe is
 stable for up to three months from the date of
 shipment.
- Once reconstituted, the PBS solution is stable up to 14 days when stored at 2-8 °C.

Property	Specification	
MW	~ 106,000 g mol ⁻¹	
Fluorescence ¹ • Emission	770 nm	
Absorbance ¹	750 nm	
Purity ²	>90%	
Appearance	Blue solid	

- 1. Absorbance and fluorescence maxima in 1xPBS.
- 2. As determined by RP-HPLC, measuring absorbance at 750 nm.



IN VIVO IMAGING & APPLICATIONS

- The recommended procedure for in vivo imaging with IVISense™ Transferrin Receptor 750 Fluorescent Probe is administration via intravenous injection and imaging 24 hours post injection.
- The tissue half-life of IVISense™ Transferrin Receptor 750 Fluorescent Probe is approximately 24 hours. Repeat injection and Imaging may be performed every 4 days for longitudinal studies. It is recommended that a pre-Injection baseline image be taken prior to re-injection and imaging if repeat injections are to be performed less than 1 week apart.

The information provided in this document is for reference purposes only and may not be all-inclusive. Revvity, Inc., its subsidiaries, and/or affiliates (collectively, "Revvity") do not assume liability for the accuracy or completeness of the information contained herein. Users should exercise caution when handling materials as they may present unknown hazards. Revvity shall not be liable for any damages or losses resulting from handling or contact with the product, as Revvity cannot control actual methods, volumes, or conditions of use. Users are responsible for ensuring the product's suitability for their specific application. REVVITY EXPRESSLY DISCLAIMS ALL WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, REGARDLESS OF WHETHER ORAL OR WRITTEN, EXPRESS, OR IMPLIED, ALLEGEDLY ARISING FROM ANY USAGE OF ANY TRADE OR ANY COURSE OF DEALING, IN CONNECTION WITH THE USE OF INFORMATION CONTAINED HEREIN OR THE PRODUCT ITSELF
NEV10091-R Rev01